IRE ablation of locally advanced pancreatic cancer tumors is a safe and feasible primary local treatment in unresectable, locally advanced disease. Confirming these early results must occur in a planned phase II investigational device exemption (IDE) study to be initiated in 2012.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2012) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: